Regeneron Pharmaceuticals, Inc. (REGN) Earnings Call Transcripts
Regeneron Pharmaceuticals, Inc.'s Latest Earnings Call - October 1, 2026
In the third quarter of fiscal year 2026, Regeneron Pharmaceuticals announced an expanded collaboration with Sanofi, which includes the development of next-generation type 2 inflammatory disease therapies. The deal involves a $1 billion upfront payment and potential milestone payments of up to $7 billion, indicating strong confidence in the pipeline. Management highlighted that Dupixent's annualized sales are now above EUR 20 billion, reinforcing its position as a leading treatment in its category, while signaling a commitment to maintaining leadership in immunology through innovative product development.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | EUR 5.2B (beat) |
| Upfront Payment | $1B (positive) |
| Total Potential Payments | $8B (positive) |
| Dupixent Annual Sales | EUR 20B (positive) |
| Market Size Projection | $20B (positive) |
| Advanced Therapy Penetration | 50% (positive) |
Guidance from management
Regeneron and Sanofi aim to accelerate the development of next-generation therapies, with pivotal studies for the long-acting IL-13 expected to start in late 2027 or early 2028. Management expressed confidence in maintaining leadership in immunology through this collaboration.
What management said
For Sanofi's investors, we would like to remind you that information presented in this call contains forward-looking statements, which are subject to substantial risks and uncertainties that may cause actual results to differ materially. We encourage you to read the disclaimer in the presentation, and we also refer you to our Form 20-F on file with the U.S. SEC and our French universal registration document. Let me...
Yes. Thanks for the question, Evan. Look, we do have a lot of money on the balance sheet. I'd like to say, because we're lucky to have George's genius inventing our molecules so we don't have to throw out money on poor business development discussions. But we're always open minded. And as far as the transaction with Sanofi, it was just a matter of creating a fair relationship, and that's what the payment was intended...
What analysts pressed on
Analysts raised concerns about the competitive landscape, particularly regarding potential biosimilars to Dupixent and the timing of market entry for new therapies. There were inquiries about the strategic rationale behind the financial terms of the collaboration and the implications for Dupixent's exclusivity.
Main topics on the call
- Expanded Collaboration with Sanofi — Regeneron and Sanofi have extended their collaboration to include four new next-generation antibodies targeting type 2 inflammatory diseases. Leonard Schleifer stated, "Today, we are opening a new chapter" in their partn...
- Dupixent Sales Performance — Dupixent continues to perform exceptionally well, with global net sales of EUR 5.2 billion in Q2 2026, annualizing above EUR 20 billion. Management noted that it is the #1 biologic prescribed across multiple specialties,...
- Market Growth Potential — Management projects the U.S. atopic dermatitis market to reach approximately $20 billion by 2032, with advanced therapy penetration expected to exceed 50% by 2040. Belen Garijo stated, "There are many opportunities for g...
- Financial Terms of the New Agreement — The new agreement includes a $1 billion upfront payment and up to $7 billion in milestone payments, with both companies sharing development and commercialization costs equally. François-Xavier Roger remarked, "This refle...
Read the full Regeneron Pharmaceuticals, Inc. transcript (October 1, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 138 calls on record spanning January 13, 2020 to October 1, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 138 Regeneron Pharmaceuticals, Inc. earnings call transcripts on record, spanning January 13, 2020 to October 1, 2026. Based on this history, Regeneron Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated October 1, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- REGN
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 138
- First call
- January 13, 2020
- Most recent
- October 1, 2026
- Reporting cadence
- quarterly